PhRMA Backs Merck In 3rd Circ. Over Nixed Fosamax Claims
Pharmaceutical Research and Manufacturers of America has asked the Third Circuit to affirm the dismissal of any multidistrict litigation claims over Merck's osteoporosis drug Fosamax predating a labeling revision by the...To view the full article, register now.
Already a subscriber? Click here to view full article